* Olema Pharmaceuticals Inc OLMA.OQ OLMA.O is expected
to show
no change in quarterly revenue when it reports results on
August 6 (estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Olema Pharmaceuticals
Inc is
for a loss of 55 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Olema
Pharmaceuticals Inc is $29.00, above its last closing price
of $16.46.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.55 -0.55 -0.56 Missed -2.6
Dec. 31 2024 -0.48 -0.48 -0.49 Missed -1.9
Sep. 30 2023 -0.50 -0.51 -0.48 Beat 6.1
Jun. 30 2023 -0.72 -0.73 -0.49 Beat 32.6
Mar. -0.71 -0.66 -0.70 Missed -5.5
31 2023
Dec. 31 2022 -0.62 -0.65 -0.65 Met 0.3
Sep. 30 2022 -0.76 -0.77 -0.57 Beat 25.8
Jun. 30 2022 -0.65 -0.64 -0.82 Missed -27.7
This summary was machine generated August 2 at 11:06 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)